Cited by 112Gastrointestinal motility and disordersDiabetes Treatment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., KLEIN, P. D.·2002·Neurogastroenterology & Motility

DOI 10.1046/j.1365-2982.2002.00311.x

Open this paper in CoChat — free account

Abstract

Pramlintide delays gastric emptying, possibly by a centrally mediated mechanism. Our aim was to determine whether the effects of pramlintide on gastric emptying differ in people with type 1 or type 2 diabetes who had no history of complications. Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 microg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects. Gastric emptying of solids was measured by 13C-Spirulina breath test. Plasma pancreatic polypeptide (HPP) response to the test meal was also measured. Relative to placebo [t 50% 91 +/- 6 min (means +/- SEM)], pramlintide equally delayed gastric emptying following 30 or 60 microg t.i.d. (268 +/- 37 min, 329 +/- 49 min, respectively; P < 0.01]. Postprandial HPP levels were lower in response to 30 and 60 microg pramlintide compared to placebo. There were no significant differences in the effects on gastric emptying or HPP levels between type 1 and type 2 diabetic subjects. Pramlintide delays gastric emptying in diabetes unassociated with clinically detected complications. Further studies are needed in diabetic patients with impaired gastric motor function.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2982.2002.00311.x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Predicting basal metabolic rate, new standards and review of previous work.
Wn, S. (1985) · PubMed · Cited by 2,955
A Patient Questionnaire to Identify Bowel Disease
Talley, N. J., Phillips, S. F., Melton, L. J., Wiltgen, C., & Zinsmeister, A. R. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-8-671 · Cited by 444
Self-citation
Effect of Proximal Gastric, Complete Gastric, and Truncal Vagotomy on Canine Gastric Electric Activity, Motility, and Emptying
Wilbur, B. G., & Kelly, K. A. (1973) · Annals of Surgery · doi:10.1097/00000658-197309000-00009 · Cited by 285
In vitro autoradiographic localization of amylin binding sites in rat brain
Sexton, P. M., Paxinos, G., Kenney, M. A., Wookey, P. J., & Beaumont, K. C. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90388-3 · Cited by 277
beta-cell apoptosis: stimuli and signaling.
Mandrup-Poulsen, T. R. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s58 · Cited by 254
Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes
Permert, J., Larsson, J., Westermark, G. T., Herrington, M. K., Christmanson, L., Pour, P. M., Westermark, P., & Adrian, T. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402033300503 · Cited by 239
Natural history of diabetic gastroparesis.
Kong, M., Horowitz, M., Jones, K. L., Wishart, J. M., & Harding, P. E. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.503 · Cited by 228
High affinity amylin binding sites in rat brain.
Beaumont, K. C., Kenney, M. A., Young, A. A., & RINK, T. J. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13212-4 · Cited by 208
Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
Young, A. A., Gedulin, B. R., Vine, W., Percy, A., & RINK, T. J. (1995) · Diabetologia · doi:10.1007/bf00401833 · Cited by 184
Dose-response for glucagonostatic effect of amylin in rats
Gedulin, B. R., RINK, T. J., & Young, A. A. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90170-0 · Cited by 180

Show all 41 references

Research works printed but not linked: 3

10.1210/jc.85.8.2822 · DOI
10.1007/s001250050331 · DOI
MannonP TaylorIL.The pancreatic polypeptide family. In:Gut Peptides.Walsh JH Dockray GJ eds. New York: Raven Press 1994: 341–70.

Sorted by citations

Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citation
Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies
Rao, S. S. C., Camilleri, M., Hasler, W. L., Maurer, A. H., Parkman, H. P., Saad, R., Scott, S. M., Simrén, M., Soffer, E., & Szarka, L. A. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01612.x · Cited by 383
Self-citation
Review article: the role of gastric motility in the control of food intake
Janssen, P., Berghe, P. V., Verschueren, S., Lehmann, A., Depoortere, I., & Tack, J. F. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04609.x · Cited by 360
Diabetic Gastroparesis
Camilleri, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp062614 · Cited by 329
Self-citation
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Integrated Upper Gastrointestinal Response to Food Intake
Camilleri, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.023 · Cited by 248
Self-citation
Gastrointestinal motility disorders in neurologic disease
Camilleri, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143771 · Cited by 211
Self-citation
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients
Hollander, P. A., Maggs, D. G., Ruggles, J. A., Fineman, M. S., Shen, L. Z., Kolterman, O., & Weyer, C. (2004) · Obesity Research · doi:10.1038/oby.2004.76 · Cited by 191
Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years: Figure 1
Kashyap, P., & Farrugia, G. (2010) · Gut · doi:10.1136/gut.2009.199703 · Cited by 175
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Ryan, G. J., Jobe, L. J., & Martin, R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.10.009 · Cited by 161
Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes
WEINZIMER, S. A., Sherr, J. L., Cengiz, E., Kim, G. E., Ruiz, J., CARRIA, L. R., Voskanyan, G. R., Roy, A., & Tamborlane, W. V. (2012) · Diabetes Care · doi:10.2337/dc12-0330 · Cited by 137
Gastrointestinal hormones and regulation of gastric emptying
Camilleri, M. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000448 · Cited by 130
Self-citation
Gastroparesis: Clinical Update. CME
Park, M. I., & Camilleri, M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00640.x · Cited by 129
Self-citation
Chronic nausea and vomiting: evaluation and treatment
Lacy, B. E., Parkman, H. P., & Camilleri, M. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0039-2 · Cited by 133
Self-citation
Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions
Hays, N. P., Galassetti, P. R., & Coker, R. H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.02.003 · Cited by 125
Metoclopramide in the treatment of diabetic gastroparesis
Lee, A. A., & Kuo, B. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.41 · Cited by 116
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108
Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes
Weyer, C., Gottlieb, A., Kim, D. D. H., Lutz, K., Schwartz, S. L., Gutiérrez, M. E. H., Wang, Y., Ruggles, J. A., Kolterman, O., & Maggs, D. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3074 · Cited by 108
Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.
Mack, C. M., Wilson, J., Athanacio, J., Reynolds, J. M., Laugero, K., Guss, S., Vu, C., Roth, J., & Parkes, D. (2007) · American Journal of Physiology. Regulatory Integrative and Comparative Physiology · doi:10.1152/ajpregu.00297.2007 · Cited by 115
Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes
Bharucha, A. E., Kudva, Y., Basu, A., Camilleri, M., Low, P. A., Vella, A., & Zinsmeister, A. R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.06.034 · Cited by 105
Self-citation
Pramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 102
The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes
Heptulla, R. A., Rodríguez, L. M., Bomgaars, L. R., & Haymond, M. W. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1100 · Cited by 88
Role and Cytotoxicity of Amylin and Protection of Pancreatic Islet β-Cells from Amylin Cytotoxicity
Kiriyama, Y., & Nochi, H. (2018) · Cells · doi:10.3390/cells7080095 · Cited by 88
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
Hoogwerf, B. J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
Role of Amylin in Type 1 and Type 2 Diabetes
Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 87
Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus
Halland, M., & Bharucha, A. E. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.021 · Cited by 85
Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
Gedulin, B. R., Jodka, C. M., Herrmann, K., & Young, A. A. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.004 · Cited by 81
Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 79
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study
Maggs, D. G., Fineman, M. S., Kornstein, J., Burrell, T., Schwartz, S. L., Wang, Y., Ruggles, J. A., Kolterman, O., & Weyer, C. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.419 · Cited by 77
Inhibition of Gastric Emptying
Young, A. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52006-4 · Cited by 79
Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes
Ceriello, A., Piconi, L., Quagliaro, L., Wang, Y., Schnabel, C. A., Ruggles, J. A., Gloster, M., Maggs, D. G., & Weyer, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.632 · Cited by 75
Pramlintide in the Treatment of Diabetes Mellitus
Edelman, S. V., Maier, H., & Wilhelm, K. (2008) · BioDrugs · doi:10.2165/0063030-200822060-00004 · Cited by 68
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care · doi:10.2337/dc09-0395 · Cited by 66
Amylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 66
Mango modulates body fat and plasma glucose and lipids in mice fed a high-fat diet
Lucas, E. A., Li, W., Peterson, S., Brown, A., Kuvibidila, S. R., Perkins-Veazie, P. M., Clarke, S. L., & Smith, B. J. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002066 · Cited by 57
IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants
Denroche, H. C., & Verchere, C. B. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0138 · Cited by 53
Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide
Mack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 51
Diabetes mellitus and gastric emptying: questions and issues in clinical practice
Samsom, M., Bharucha, A. E., Gerich, J. E., Herrmann, K., Limmer, J., Linke, R., Maggs, D. G., Schirra, J. R. J., Vella, A. V., Wörle, H., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.974 · Cited by 49
Self-citation
Novel Pharmacologic Agents for Type 2 Diabetes
Uwaifo, G. I., & Ratner, R. E. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.006 · Cited by 45
Pathophysiology, Aetiology and Treatment of Gastroparesis
Sullivan, A., Temperley, L., & Ruban, A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06287-2 · Cited by 44
Living with the enemy: from protein-misfolding pathologies we know, to those we want to know
Emwas, A.-H. M., Alghrably, M., Dhahri, M., Sharfalddin, A. A., Alsiary, R., Jaremko, M., Faa, G., Campagna, M., Congiu, T., Piras, M., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101391 · Cited by 43
Diabetic Gastroparesis and Its Impact on Glycemia
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.007 · Cited by 43
Diabetic gastroparesis—Backwards and forwards
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06573.x · Cited by 40
Weight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 40
Pramlintide Lowered Glucose Excursions and Was Well-Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized, Single-Blind, Placebo-Controlled, Crossover Study
Chase, H. P., Lutz, K., Pencek, R., Zhang, B., & Porter, L. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.03.012 · Cited by 39
Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Larsen, A. T., Mohamed, K. E., Sonne, N., BREDTOFT, E.-M., Andersen, F., Karsdal, M. A., & Henriksen, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113842 · Cited by 40
Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight
Karl, D. M., Philis‐Tsimikas, A., Darsow, T., Lorenzi, G. M., Kellmeyer, T., Lutz, K., Wang, Y., & Frías, J. P. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0013 · Cited by 38
Pramlintide for the Treatment of Diabetes Mellitus
Kleppinger, E. L., & Vivian, E. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c387 · Cited by 37
Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function
Hinshaw, L., Schiavon, M., Mallad, A., Man, C. D., Basu, R., Bharucha, A. E., Cobelli, C., Carter, R. E., Basu, A., & Kudva, Y. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00199.2014 · Cited by 38
What are the important subsets of gastroparesis?
Camilleri, M., Grover, M., & Farrugia, G. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01942.x · Cited by 32
Self-citation
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
Wysham, C., Lush, C. W., Zhang, B., Maier, H., & Wilhelm, K. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253537 · Cited by 32
Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without Type 2 diabetes
Chowdhury, S., Reeds, D. N., Crimmins, D. L., Patterson, B. W., Laciny, E., Wang, S., Tran, H. D., Griest, T. A., Rometo, D. A., Dunai, J., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00383.2013 · Cited by 28
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Diabetic gastroparesis: Therapeutic options
Alam, U., Asghar, O., & Malik, R. A. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0010-8 · Cited by 26
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 28
Self-citation
Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study
Pajot, G. J., Camilleri, M., Calderón, G., Davis, J. A., Eckert, D. J., Burton, D. D., & Acosta, A. J. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0593-8 · Cited by 23
Self-citation
New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar, M. (2011) · PubMed · Cited by 21
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
Mathiesen, D. S., Lund, A., Holst, J. J., Knop, F. K., Lutz, T. A., & Bagger, J. I. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1261 · Cited by 21
In Silico Design of Optimal Ratio for Co-Administration of Pramlintide and Insulin in Type 1 Diabetes
Micheletto, F., Man, C. D., Kolterman, O., Chiquette, E., Herrmann, K., Schirra, J., Kovatchev, B., & Cobelli, C. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0054 · Cited by 24
Gastroparesis
Bouras, E. P., Roque, M. I. V., & Aranda‐Michel, J. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533613491982 · Cited by 21
Clinical Studies
Young, A. J. (2005) · Advances in pharmacology · doi:10.1016/s1054-3589(05)52018-0 · Cited by 20
Pramlintide: Clinical Strategies for Success
Alrefai, H. A., Latif, K. A., Hieronymus, L. B., Weakley, C. R., & Moss, R. J. (2010) · Diabetes Spectrum · doi:10.2337/diaspect.23.2.124 · Cited by 16
Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times Relative to Subcutaneous Injection of Pramlintide in Subjects With Type 2 Diabetes
Kellmeyer, T., Kesty, N. C., Wang, Y., Frías, J. P., & Fineman, M. S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007300949 · Cited by 16
Pathogenesis and management of diabetic gastroparesis: An updated clinically oriented review
Uppaluri, S., Jain, M. A., Ali, H., Shingala, J., Amin, D., Ajwani, T., Fatima, I., Patel, N., Kaka, N., Sethi, Y., et al. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102994 · Cited by 14
Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 16
Adjunctive Therapy with Pramlintide in Patients with Type 1 or Type 2 Diabetes Mellitus
Nogid, A., & Pham, D. Q. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.11.1626 · Cited by 14
Primer on Pramlintide, an Amylin Analog
Traina, A. N., & Kane, M. P. (2011) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721711403011 · Cited by 12
Pramlintide for post‐bariatric hypoglycaemia
Sheehan, A. L., Goldfine, A. B., Bajwa, M., Wolfs, D., Kozuka, C., Piper, J., Fowler, K. M., & Patti, M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14665 · Cited by 13
Amylin
Phillips, L. K., & Horowitz, M. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216969.59375.39 · Cited by 12
Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management
Lingvay, I., Rhee, C., & Raskin, P. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_10 · Cited by 12
A contemporary biological pathway of islet amyloid polypeptide for the management of diabetic dementia
Sah, S. K., Samuel, V. P., Dahiya, S., Singh, Y., Gilhotra, R. M., Gupta, G., Mishra, A., Sharma, R. K., Kumar, G. S., Sreeharsha, N., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.022 · Cited by 13
Amylin reduces plasma glucagon concentration in cats
Furrer, D., Kaufmann, K., Reusch, C. E., & Lutz, T. A. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.02.011 · Cited by 11
Effects of Glutamine on Gastric Emptying of Low- and High-Nutrient Drinks in Healthy Young Subjects—Impact on Glycaemia
Du, Y., Piscitelli, D., Ahmad, S., Trahair, L. G., Greenfield, J. R., Samocha‐Bonet, D., Rayner, C. K., Horowitz, M., & Jones, K. L. (2018) · Nutrients · doi:10.3390/nu10060739 · Cited by 10
Gastroparesis: an evidence-based review for the bariatric and foregut surgeon
Bardaro, S. J., Guerron, A. D., Romanelli, J. R., Soriano, I. S., King, K., Gibbs, K. E., Petrick, A. T., Menzo, E. L., Rosenthal, R. J., Kennedy, C. M., et al. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.02.018 · Cited by 9
Effects of pramlintide on energy intake and food preference in rats given a choice diet
Kern, K. A., DiBrog, A. M., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113541 · Cited by 7
Physiological models for artificial pancreas development
VISENTIN, R., Schiavon, M., Basu, R., Basu, A., Man, C. D., & Cobelli, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00015-6 · Cited by 8
Impact of gastric emptying and small intestinal carbohydrate absorption on glycemia in health and diabetes: therapeutic implications
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments
Camilleri, M. (2024) · The Journal of Physiology · doi:10.1113/jp287535 · Cited by 7
Self-citation
Interventions That Affect Gastrointestinal Motility in Hospitalized Adult Patients
Asrani, V. M., Yoon, H. D., Megill, R. D., Windsor, J. A., & Petrov, M. S. (2016) · Medicine · doi:10.1097/md.0000000000002463 · Cited by 6
Retracted
Neuroprotective Mechanisms of Amylin Receptor Activation, Not Antagonism, in the APP/PS1 Mouse Model of Alzheimer’s Disease
Corrigan, R. R., Labrador, L., Grizzanti, J., Mey, M., Piontkivska, H., & Casadesús, G. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221057 · Cited by 5
Non-Insulin Treatments for Diabetes
Angueira-Serrano, E. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f2cb · Cited by 3
Prokinetic agents for gastroparesis
Parkman, H. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00024-7 · Cited by 4
Relation between serum amylin level and epilepsy
Benlier, N., Özer, G., & Orhan, N. (2020) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-020-00164-5 · Cited by 4
Chronic pramlintide decreases feeding via a reduction in meal size in male rats
Kern, K. A., DiBrog, A. M., Kaur, K., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171197 · Cited by 3
Incretins and amylin in pediatric diabetes
Wood, J., & Silverstein, J. H. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328362fdfb · Cited by 3
Use of continuous glucose monitoring to introduce adjunctive pramlintide therapy in a patient with type 1 diabetes: A case study
Walker, T. C. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00652.x · Cited by 3
Medical Management of Obesity as it Affects Reflux
Haddad, J. D., & Shah, S. L. (2021) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161211069183 · Cited by 3
DIABETES MELLITUS
Rizza, R. A., & Vella, A. V. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50041-x · Cited by 3
Self-citation
A Review of Pramlintide in the Management of Diabetes
Messer, C., & Green, D. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2369 · Cited by 2
Diabetic gastroparesis: Therapeutic options
Alam, U., Asghar, O., & Malik, R. A. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-002-82010 · Cited by 2
Study of Diabetic Gastroparesis
Bharucha, A. E. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.02.011 · Cited by 2
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 1
The I slet Amyloid Polypeptide hormone Amylin: Its function, effec ts and uses in medicine
Roberson, S. W. (2013) · Cited by 1
Medical Management of Gastroparesis: Diet and Medications
Jacob, D. A., & Camilleri, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-96122-4_69 · Cited by 1
Self-citation
Prokinetic Agents for Gastroparesis
Parkman, H. P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-552-1_22 · Cited by 1
Frequent Occurrence of Rapid as Well as Delayed Gastric Emptying of a Corn Flakes and Milk Meal in Clinical Patients With Gastrointestinal Symptoms
Santiago-Maldonado, I. M., & Phillips, W. T. (2007) · Clinical Nuclear Medicine · doi:10.1097/01.rlu.0000255028.99539.d3 · Cited by 1
The Physiology and Pharmacology of Diabetic Gastropathy Management
Dolan, R. D., Rohani, T. S., Muttineni, D., & Mashimo, H. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00045-1 · Cited by 1
Gastrointestinal Manifestations of Diabetes
Bharucha, A. E., & Camilleri, M. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch46 · Cited by 1
Self-citation
Gastrointestinal and Autonomic Complications of Diabetes Mellitus
Vella, A. V., & Camilleri, M. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-23 · Cited by 1
Self-citation

Authors: VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D.
Affiliations: Mayo Clinic (US)
Nashville State Community College (US)
Corresponding author: CAMILLERI, M.
ORCID: VELLA, A.
CAMILLERI, M.
BURTON, D. D.
KLEIN, P. D.
Venue: Neurogastroenterology & Motility
Publisher: Wiley
Published: 2002-04
Volume: 14
Issue: 2
Pages: 123-131
ISSN: 1350-1925 (ISSN-L)
1365-2982
DOI: 10.1046/j.1365-2982.2002.00311.x
OpenAlex: W2060927585
Cited by: 112
References: 41
Citations by year: 2026: 3 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 3
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 25 d)
Locations: Neurogastroenterology & Motility (publishedVersion)
PubMed (publishedVersion)
Funders: Mayo Clinic
Amylin Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK029953, R01-DK29953, R01 DK-54681, K24-DK-02683, R01DK054681)
National Center for Research Resources (RR-00585, M01RR000585)
NIH Clinical Center
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: pramlintide, amylin analogues, gastric emptying, type 1 diabetes, type 2 diabetes, pancreatic polypeptide, postprandial hormone response, gastric motility, subcutaneous administration
MeSH terms: Aged, Amyloid, Anti-Ulcer Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Gastric Emptying, Humans, Hypoglycemic Agents, Male, Middle Aged, Linear Models, Cross-Over Studies, Statistics, Nonparametric, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks